APUS
AMEX Apimeds Pharmaceuticals US, Inc.$4.99 ↓ -0.03 (-0.70%) Trading Down from the previous close of $5.02, $0.27 below the day’s high of $5.25
- YTD change
- -83.38%
- vs 20-day SMA
- +71.53%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
+3.27 (+186.86%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 91.6% away from all-time highs of $59.70
- APUS is down 83% since the beginning of the year
- APUS is down 83% over the past 12 months
- APUS is up 28% over the past 1 month
- 2% of all APUS investors are betting against APUS
- Number of investors short APUS has gone down 61% versus last month
APUS reads not so good: short interest is falling month over month, the 12-month move is +182.0%.
- Previous minute
- +$0.00
- Last hour
- -$0.05
- Last 5 days
- +169.46%
- vs 8-day SMA
- +27.98%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
